Re-evaluating Methods for Assessing Differences in Response in Ileal vs. Colonic Crohn&apos;s Disease: A Post-hoc Analysis of the FITZROY Trial

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

Clin Gastroenterol Hepatol

Colombel JF, Lacerda AP, Irving PM, Panaccione R, Reinisch W, Rieder F, Steinlauf A, Schwartz D, Feng T, Dubcenco E, Anyanwu SI, Laroux FS, Cunneen C, Powell N

doi: 10.1016/j.cgh.2024.08.032

Inflammatory Bowel Disease

IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials

Am J Gastroenterol

Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S

doi: 10.14309/ajg.0000000000003406

Further Publications

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

Gut

Adler J, Gadepalli S, Rahman M, Kim S

doi: 10.1136/gutjnl-2024-333280

Inflammatory Bowel Disease

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease

Inflamm Bowel Dis

Fumery M, Savoye G, Sarter H, Dupont-Lucas C, Bertrand V, Wils P, Richard N, Guillon N, Gower-Rousseau C, Turck D, Ley D, Leroyer A, EPIMAD group

doi: 10.1093/ibd/izaf133

Inflammatory Bowel Disease

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease

Insights Imaging

Sakai NS, Plumb AA, Ahmed N, Chowdhury K, Kilic Y, Hameed M, Patel A, Bhagwanani A, Helbren E, Hyland R, Bhatnagar G, Sidhu H, Lambie H, Franklin JM, Mohsin M, Thomson E, Boone D, Tolan D, Rahman S, Ding N, Moran GW, Bloom S, Hart A, Menys A, Travis S, Halligan S, Taylor SA, Motility trial investigators

doi: 10.1186/s13244-025-01930-w

Inflammatory Bowel Disease

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Gastroenterology

Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Zou G, Yuan Y, Sands BE, Feagan BG, Dulai PS, Narula N, Ma C, Jairath V

doi: 10.1053/j.gastro.2024.10.009

Inflammatory Bowel Disease

After surgically induced remission, ileal and colonic mucosa-associated microbiota predicts Crohn's disease recurrence

Clin Gastroenterol Hepatol

Rocha CH, Turpin W, Borowski K, Stempak JM, Sabic K, Gettler K, Tastad C, Chasteau C, Korie U, Hanna M, Khan A, Mengesha E, Bitton A, Schwartz MB, Barrie A, Datta LW, Lazarev M, Brant SR, Rioux JD, McGovern DPB, Duerr RH, Schumm LP, Cho JH, Silverberg MS

doi: 10.1016/j.cgh.2024.06.022

Inflammatory Bowel Disease

Inflammation-related Proteins Support Diagnosis of Inflammatory Bowel Disease and Are Modified by Exclusive Enteral Nutrition in Children With Crohn's Disease, Especially of Ileal Phenotype

Inflamm Bowel Dis

White B, Svolos V, Gervais L, Jatkowska A, Nichols B, MacDonald J, Seenan JP, Hansen R, Russell RK, Milling S, Gerasimidis K

doi: 10.1093/ibd/izae107

Inflammatory Bowel Disease

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

J Crohns Colitis

Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB

doi: 10.1093/ecco-jcc/jjaf060

Related content

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials

IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

Long-Term Outcome of Colonic and Ileal Crohn's Disease: A Two-Decade Population-Based Study in Pediatric-Onset Disease

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

After surgically induced remission, ileal and colonic mucosa-associated microbiota predicts Crohn's disease recurrence

Inflammation-related Proteins Support Diagnosis of Inflammatory Bowel Disease and Are Modified by Exclusive Enteral Nutrition in Children With Crohn's Disease, Especially of Ileal Phenotype

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)